O

Ossium Health

Stem cell therapies from deceased donors

Production Supervisor - HPC, Marrow

Full-Time
No salary listed
Mid
Bachelor's
Indianapolis, IN, USA
In Person
Biology & BiotechBioprocess & Biomanufacturing
Company Does Not Provide H1B Sponsorship

About the job

Requirements
  • A high school diploma is required.
  • At least 2 years of experience managing people is required.
  • At least 4 years of manufacturing experience is required.
  • Knowledge of manufacturing operations in a regulated environment is required.
  • Scientific aptitude and the ability to clearly and thoroughly document all work on existing forms and records are required.
  • A high level of attention to detail in operations and documentation is required.
  • Written and oral communication skills are required.
  • The ability to operate with a high level of organization and time management in a dynamic startup environment is required.
  • The position requires the ability to work in a moderately noisy environment, around biohazardous materials and chemicals, and primarily aseptically in a controlled environment with limited breaks.
  • The position requires special gowning covering the head, face, hands, feet, and body.
  • The position requires the ability to lift, push, pull, or carry up to 50 pounds.
  • The position requires sufficient manual dexterity, hand and finger coordination, wrist mobility and stability, and grip strength to safely and accurately handle, feel, grasp, manipulate, and operate objects, manual and power tools, equipment, and controls.
  • The position requires the ability to sit, stand, walk, squat, balance, climb, stoop, kneel, crouch, and reach with the arms.
  • A pre-employment physical examination is required after a conditional offer to evaluate the ability to perform the essential functions safely.
Responsibilities
  • Oversee daily production of HPC, Marrow, including staff scheduling and troubleshooting processing issues.
  • Lead daily first-shift huddles and escalate safety, quality, delivery, cost, and people issues during the Tier 2 huddle.
  • Meet regularly with direct reports and escalate issues or concerns.
  • Perform or verify assigned tasks in the production of HPC, Marrow.
  • Ensure all production staff complete required training.
  • Provide ongoing coaching and recognition to direct staff.
  • Review timesheets of direct reports.
  • Review bone marrow production batch records and associated documentation.
  • Perform allocation and authorization reviews for incoming donors and sample requests.
  • Ensure production activities comply with current Good Tissue Practices, AATB standards, and other relevant regulations.
  • Author or assist with drafting and revising departmental procedures.
  • Oversee cryopreservation and initial inventory of HPC, Marrow products and samples in freezers.
  • Perform quality monitoring, including manipulating databases, documents, and spreadsheets for business reporting, and communicate processing and product trends to production specialists.
  • Maintain production areas and records in an inspection-ready state.
  • Work with the Sterile Processing and Equipment teams to monitor production equipment and tools and ensure they are clean, operational, and within calibration and preventive-maintenance schedules.
  • Work with Quality Assurance to complete event reports, deviations, corrective and preventive actions, and change controls.
  • Work with Quality Control to submit sample requests and prepare reports.
  • Interact with management to provide updates, results, suggestions, and observations about work areas and processes.
Desired Qualifications
  • A Bachelor of Science or Bachelor of Arts degree in biological sciences or equivalent is preferred.
  • Knowledge of aseptic techniques, cleanroom environments, cellular processing, and tissue processing is preferred.
  • At least 2 years of aseptic processing or management experience is preferred.

About the company

O

Ossium Health

View
Website

Ossium Health develops cell therapies using stem cells from deceased donors to treat blood diseases and immune disorders, reduce organ transplant rejection, and address orthopedic conditions. Therapies are created through research, clinical trials, and partnerships, and distributed via collaborations and licensing to bring proprietary products to patients. The company differentiates itself by leveraging deceased-donor stem cells and close ties with organ procurement networks, building a portfolio across hematology, immunology, transplantation, and orthopedics. The goal is to make effective donor-derived cell therapies more accessible to improve health, vitality, and longevity.

Company Size

51-200

Company Stage

Series C

Total Funding

$134.9M

Headquarters

San Francisco, California

Founded

2016

Get referred to Ossium Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • January 2026 PRESERVE I data showed rapid engraftment and no infusion-related toxicity.
  • HOPE expanded access broadens transplant-center relationships beyond the five active PRESERVE sites.
  • Series C funding and a 34,000-square-foot facility support scaling, manufacturing, and clinical throughput.

What critics are saying

  • PRESERVE I enrolled only four patients by January 2026, exposing thin clinical evidence.
  • OSSM-007 remains unapproved, so Ossium still depends on trial execution and regulators.
  • Any BARDA option nonexercise after 2029 leaves Ossium without its largest visible demand engine.

What makes Ossium Health unique

  • First-mover banked deceased-donor bone marrow creates immediate, off-the-shelf graft access.
  • BARDA selected Ossium in 2024 for radiation-and-nuclear emergency marrow countermeasures.
  • Indianapolis FDA-registered manufacturing and CLIA labs support a vertically integrated platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Medical, dental and vision coverage
  • 401(k) Company Match
  • Stock Options
  • Unlimited Paid Time Off
  • Employer paid life insurance and long term disability
  • Gym membership/recreational sports reimbursements

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
GlobeNewswire
Oct 14th, 2026
Ossium Health data on on-demand organ donor bone marrow selected as a Top Poster at the 2026 AABB Annual Meeting.

Ossium Health data on on-demand organ donor bone marrow selected as a Top Poster at the 2026 AABB Annual Meeting. Updated data show stem cell viability is preserved through cryopreservation and 100% engraftment in evaluable transplant recipients. SAN FRANCISCO, Oct. 14, 2026 (GLOBE NEWSWIRE) - Ossium Health, a bioengineering company that built the world's first bank of organ donor-derived bone marrow, announced that its abstract, "On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors," has been selected as a Top Poster at the 2026 Association for the Advancement of Blood & Biotherapies (AABB) Annual Meeting in Atlanta. The poster will be featured in the curated Top Posters Tour, "Innovations in Cellular Therapies," on Sunday, Oct. 18, and displayed in a dedicated Top Poster area throughout the meeting. "Patients facing transplant should not have to wait on a donor search, and our bank is built so they don't have to." "AABB sets the standards for biobanking and cellular therapy, so having this community recognize our work as a Top Poster means a great deal to our team," "These data show that high-quality bone marrow from deceased organ donors can be recovered, banked and delivered when patients need it, often within 48 hours," "Patients facing transplant should not have to wait on a donor search, and our bank is built so they don't have to." AABB is an international, not-for-profit organization dedicated to advancing transfusion medicine and biotherapies, with a professional community in more than 80 countries. Its annual meeting, held Oct. 17-19 this year, brings together physicians, nurses, scientists, researchers, medical technologists and other health care professionals from around the world. "AABB sets the standards for biobanking and cellular therapy, so having this community recognize our work as a Top Poster means a great deal to our team," said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. Ossium recovers bone marrow from the vertebrae of screened and consented deceased organ donors, then cryopreserves and banks it as HPC, Marrow so it is ready for allogeneic hematopoietic cell transplantation on demand. To date, 29 patients have been transplanted with Ossium's bone marrow, some within 48 hours of a physician's request. The poster updates data previously published in Cytotherapy, with continued accrual following Ossium's process improvements in July 2024. Key findings include: * Viability: Median post-thaw CD34+ stem cell viability was 86%, with no significant difference between pre-freeze and post-thaw samples. * Potency: Post-thaw colony-forming unit assays showed that the cells retain their ability to grow and differentiate. * Engraftment: 100% of the 24 patients with engraftment data available at the time of abstract submission have engrafted. * Safety: No clinically significant adverse events attributable to the product or excipients were reported. The authors conclude that deceased donor bone marrow is a feasible and scalable off-the-shelf graft source for allogeneic hematopoietic cell transplantation, and a promising new source of starting material for emerging cell therapies. "These data show that high-quality bone marrow from deceased organ donors can be recovered, banked and delivered when patients need it, often within 48 hours," said Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President of Ossium Health. "Patients facing transplant should not have to wait on a donor search, and our bank is built so they don't have to." Presentation details * Title: On-demand, High-quality Hematopoietic Stem Cells from Deceased Organ Donors (P-BT-2) * Session: Curated Top Posters Tour: Innovations in Cellular Therapies * Date and time: Sunday, Oct. 18, 2026, 12:15-1:00 p.m. ET * Location: Georgia World Congress Center, Exhibit Halls B2-B3, Biotherapies Pavilion * Presenter: Meghann Pierce, DNP, APRN, ANP-C, Medical Science Liaison, Ossium Health * Authors: Erik J. Woods, PhD; Kevin Blankenberger; Nicholas Weinstein; Vicki Graves; Hans Nowak; Kelsey Musall; Sagar Munjal, MD; W. Scott Goebel, MD; Brian H. Johnstone, PhD This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract No. 75A50124C00032. About Ossium Health Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium's manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X. Media Contact: Jane Griffin Ossium Health, Inc. 415-513-5535 [email protected]

Ossium Health
Sep 22nd, 2026
In observance of World Marrow Donor Day: honoring the people who carry our donors' legacy forward.

In observance of World Marrow Donor Day: honoring the people who carry its donors' legacy forward. Every September, the World Marrow Donor Association (WMDA) marks World Marrow Donor Day, a global day to say #ThankYouDonor to the millions of people who register, donate, and give patients a second chance at life through stem cell and bone marrow donation. This year's observance falls on September 22, and Ossium Health is proud to participate as a Bronze Partner. Most World Marrow Donor Day tributes go directly to donors. Their generosity is the reason this day exists. At Ossium, its path to honoring donors looks a little different. The donors who make its work possible are deceased organ donors whose bone marrow gifts can become a source of life-saving cell therapies. While Ossium Health, Inc. cannot thank these donors ourselves, Ossium Health, Inc. can honor their generosity, remember the lives behind every donation, and recognize the people who help carry their legacy forward. Today, in observance of World Marrow Donor Day, Ossium Health, Inc. want to recognize its recovery partners. Ossium's recovery partners include organ procurement organizations and recovery professionals across the country who care for donors and donor families during some of life's most difficult moments. They approach families with compassion, help communicate what donation means and what it can make possible, coordinate the donation process, and provide support and aftercare that extends far beyond recovery. Their work creates the bridge between a family's decision to donate and the patients who may one day receive a transplant made possible by that gift. In the spirit of WMDA's Hope Heroes campaign, Ossium Health, Inc. believe these partners deserve recognition as well. Hope Heroes can be found throughout the journey to transplantation, from the people who support donors and families to those who coordinate care and ultimately help bring a stem cell therapy to a patient in need. Its recovery partners play an essential role at the very beginning of that journey by caring for the donors and families who make it all possible. Ossium Health, Inc. is grateful for every organ procurement organization that partners with Ossium and entrusts Ossium Health, Inc. with the opportunity to extend a donor's gift through bone marrow donation. Ossium Health, Inc. also want to recognize its past Top Recovery Partners of the Year, whose teams have demonstrated an extraordinary commitment to Ossium's mission and to honoring the gift of donation: 2025: Legacy of Life Hawai'i 2024: LifeGift Texas 2023: Gift of Life Michigan 2022: Donor Network of Arizona Each represents a different community, but all share something fundamental: a commitment to donors and donor families, and the possibility that one person's gift can continue to create hope for others. Thank you for caring for donor families. Thank you for honoring the wishes and generosity of donors. Thank you for trusting Ossium Health, Inc. to help carry those gifts forward. And most importantly, thank you for helping make it possible for someone else to receive a second chance at life. Join its team. At Ossium, Ossium Health, Inc. is always looking for talented, mission-driven people.

WDFX-TV
Jul 29th, 2026
Forbes names Ossium Health a 2026 Next Billion-Dollar startup.

Forbes names Ossium Health a 2026 Next Billion-Dollar startup. * 2 hrs ago Ossium Health, a bioengineering company that built the world's first bank of organ donor-derived bone marrow, has been named to the 2026 Forbes Next Billion-Dollar Startups list, Forbes' annual selection of 20 fast-growing U.S. companies it considers most likely to reach a $1 billion valuation. Produced by Forbes for the twelfth consecutive year, the list is selected from startups that are venture-backed, based in the United States, and currently valued at less than $1 billion. Of the 275 companies named to the list since its inception, 60% have gone on to become unicorns. "This recognition reflects the value of the platform we've built and the scale of the problem it addresses," said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. "Thousands of patients each year never reach transplant because no donor is available in the timeframe their disease allows. Our bank removes this wait from the critical path. As our bone marrow becomes more widely available over the next year, we expect to serve more patients and narrow the donor availability gap." Ossium has now treated 28 patients, and in every case the company's marrow took hold and began producing healthy white blood cells in the recipient, a critical milestone known as neutrophil engraftment. About Ossium Health Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, CEO, Co-Founder & President, and Erik Woods, Chief Science Officer, Co-Founder & Executive Vice President. Ossium's manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, visit ossiumhealth.com or follow the company on LinkedIn and X. Media gallery

Weston, Inc.
Apr 20th, 2026
Ossium Health's Indianapolis facility reflects the rise of life sciences real estate.

Ossium Health's Indianapolis facility reflects the rise of life sciences real estate. April 20, 2026 Indianapolis is home to Ossium Health, a biotech company which operates the world's first bone marrow bank for the treatment of diseases of the blood and immune systems. Bone marrow banking is the process of collecting, processing, and storing bone marrow stem cells so they are available for medical treatment when needed, rather than relying on live donors at the time of illness. Govenor Mike Braun toured Ossium's nearly 34,000 SF production facility at 5742 W 74th Street last week after recently announcing $1B in incentives for life sciences. The visit highlighted Ossium's innovative work and emphasized Indianapolis' potential for becoming the Silicon Valley for life sciences. The building includes multiple cleanrooms, research and development laboratories, bulk storage areas, and office space for a growing team of scientists, production specialists, and quality personnel. This type of buildout underscores a key trend in industrial real estate, which is that life sciences users require highly customized spaces that support strict regulatory standards, advanced infrastructure, and long-term scalability. Facilities like Ossium's push far beyond traditional warehouse or flex space, blending elements of industrial, lab, and office environments into a single, specialized footprint. Indianapolis continues to strengthen its position as a growing hub for life sciences and advanced manufacturing, and Weston Inc. is pleased to have Ossium as a tenant. Ask Weston Inc. any questions. Its representatives are available to help answer your questions.

Ossium Health
Mar 3rd, 2026
Forbes Selects Ossium as One of America's Best Startup Employers

Forbes selects Ossium as one of America's Best Startup Employers. For the second time in three years, Ossium Health has been named to Forbes' list of America's Best Startup Employers. This annual list highlights a select group of U.S. startups that demonstrate excellence in employee satisfaction, employer reputation, and organizational growth - criteria that reflect not only business performance, but the strength of a company's culture and its ability to attract and retain exceptional talent. At Ossium, its work is driven by a singular mission: to improve the health, vitality, and longevity of human beings through bioengineering. Achieving this mission requires bringing together individuals who are deeply committed to scientific innovation and motivated by the opportunity to make a meaningful impact on patients facing serious and life-threatening conditions. Being recognized by Forbes underscores the environment ossiumhealth.com has built: one where talented individuals can do their best work in pursuit of transformative medical advances. Its team's dedication extends beyond day-to-day responsibilities. It is reflected in the care with which ossiumhealth.com develop and deliver novel cell-based therapies, the rigor of its clinical and research programs, and the shared sense of purpose that unites its organization. ossiumhealth.com believe that fostering a mission-driven, collaborative, and supportive workplace is essential to advancing breakthroughs that save lives. "This recognition is a direct reflection of our team and the culture we've built together," said Kevin Caldwell, CEO, President & Co-founder of Ossium Health. "We've assembled a group of people who are not only exceptionally talented, but deeply committed to our mission. Their passion, integrity, and persistence are what enable us to pursue ambitious goals in bioengineering and deliver meaningful impact for patients. We're honored to be recognized alongside other outstanding startups and remain focused on building an organization where people can do the most important work of their careers." Ossium is actively growing and looking for exceptional individuals to join its team. If you're motivated by the opportunity to help pioneer the future of bioengineering and make a meaningful difference for patients, ossiumhealth.com encourage you to explore open roles at ossiumhealth.com/careers. ossiumhealth.com is grateful to its entire team for their contributions and proud to be included among this year's Best Startup Employers. Join its team. At Ossium, ossiumhealth.com is always looking for talented, mission-driven people.